Benefits of investment into modern medicines in Central-Eastern European countries

Transferability of current evidence and expressing value of innovative pharmaceuticals according to health system objectives Due to the scarcity of healthcare resources, decision-makers often expect monetary benefits - including cost savings or productivity gain - from innovative medicines. Manufact...

Full description

Saved in:
Bibliographic Details
Published in:Expert review of pharmacoeconomics & outcomes research 2014-02, Vol.14 (1), p.71-79
Main Authors: Inotai, András, Petrova, Guenka, Vitezic, Dinko, Kaló, Zoltán
Format: Article
Language:English
Subjects:
equity
financial protection
Health care expenditures
health gain
Innovations
innovative medicines
Life expectancy
middle-income countries
monetary benefit
Mortality
Pharmaceuticals
Productivity
responsiveness
sustainability
value of innovation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Transferability of current evidence and expressing value of innovative pharmaceuticals according to health system objectives Due to the scarcity of healthcare resources, decision-makers often expect monetary benefits - including cost savings or productivity gain - from innovative medicines. Manufacturers try to fulfill this expectation by expressing the benefits of innovative technologies in monetary units citing approaches from the scientific literature. Unfortunately, currently available evidence has limited relevance and transferability in Central-Eastern European (CEE) countries. This study aims to summarize how innovative pharmaceuticals in CEE countries may contribute to WHO-defined health system objectives, including health gain, equity in health, financial protection, responsiveness, equity in finance and financial sustainability. References in this study are also mainly based on international examples; therefore, additional policy research from CEE countries is necessary to validate assumptions. If CEE politicians can rely on credible arguments based on local research evidence, they may improve long-term strategies and policy decisions related to healthcare innovation.
ISSN:1473-7167
1744-8379
DOI:10.1586/14737167.2014.868314